Protein Kinase Inhibitors: all 15,766 studies that test it

Page 9 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.

• The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune ThrombocytopeniaNot yet recruitingNCT07064889Phase 2
• Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective StudyNot yet recruitingNCT07064668Phase 2
• A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)RecruitingNCT07064122Phase 1
• Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positiveNot yet recruitingNCT07063329Phase 1/2
• Curcumin & Astaxanthin for Lowering Triglyceride Readings and InflammationRecruitingNCT07063056Not applicable
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.RecruitingNCT07062965Phase 3
• Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic LeukemiaRecruitingNCT07061951Phase 2
• Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast CancerNot yet recruitingNCT07061717Phase 3
• DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)RecruitingNCT07059650Phase 1/2
• A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLCRecruitingNCT07058519Phase 2
• A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System TumorsNot yet recruitingNCT07053150Phase 2
• Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need VentilatorsRecruitingNCT07052929Phase 1/2
• Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal CancerNot yet recruitingNCT07051785Phase 2
• Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)RecruitingNCT07049926Phase 1/2
• Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis SuppurativaRecruitingNCT07049575Phase 1
• Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone MetastasesRecruitingNCT07043608Phase 2
• Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver CancerRecruitingNCT07042919Phase 1/2
• Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal CancerRecruitingNCT07042685Phase 2
• Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaRecruitingNCT07040982Phase 1
• An Open-Label, Single-Arm Exploratory Clinical Study of Everolimus for the Treatment of Vascular MalformationsRecruitingNCT07037238Phase 2
• Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney TransplantationRecruitingNCT07033858Not applicable
• Exploring a Natural Solution for Childhood ObesityNot yet recruitingNCT07033767Phase 1/2
• Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic LeukemiaRecruitingNCT07033598Phase 2
• Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)Not yet recruitingNCT07032532Phase 2
• A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung CancerNot yet recruitingNCT07031154Phase 2
• Linperlisib in the Treatment of aPRCANot yet recruitingNCT07031115Phase 2
• Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell TransplantationRecruitingNCT07025538Phase 1
• Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual DiseaseRecruitingNCT07025226Early Phase 1
• MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without ObinutuzumabRecruitingNCT07024706Phase 2
• Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1Not yet recruitingNCT07024394Phase 1/2
• A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionRecruitingNCT07023627Phase 2
• Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast CancerNot yet recruitingNCT07019337Phase 2
• A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell LymphomasRecruitingNCT07018752Phase 1/2
• Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial SpondyloarthritisNot yet recruitingNCT07018206Phase 4
• Neoadjuvant Darovasertib in Primary Uveal MelanomaRecruitingNCT07015190Phase 3
• Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLRecruitingNCT07014917Phase 2
• Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific AntibodiesRecruitingNCT07014319Phase 2
• Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular CarcinomaRecruitingNCT07014150Phase 2
• The Efficacy and Safety of Deucravacitinib in Takayasu's ArteritisNot yet recruitingNCT07013838Phase 4
• A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar PustulosisRecruitingNCT07013201Phase 2
• Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCLRecruitingNCT07012980Phase 2
• A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)RecruitingNCT07011576Phase 2
• Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin OintmentRecruitingNCT07010692Phase 1/2
• A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular CarcinomaRecruitingNCT07010497Phase 2
• A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）RecruitingNCT07010419Phase 3
• Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruitingNCT07010393Phase 4
• Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line TreatmentRecruitingNCT07007962Phase 3
• A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell TransplantRecruitingNCT07006506Phase 2
• FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF AlterationNot yet recruitingNCT07004075Phase 3
• JAK Signaling in DepressionRecruitingNCT07003997Phase 2
• Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center StudyNot yet recruitingNCT07003464Phase 2
• A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)RecruitingNCT07001384Phase 1
• ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid TumorsRecruitingNCT06998407Phase 1/2
• EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)RecruitingNCT06997588Phase 2
• Effect of Hepatic Impairment on the Pharmacokinetics of MirdametinibRecruitingNCT06997276Phase 1
• Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States PopulationRecruitingNCT06997068Phase 2
• Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder CancerRecruitingNCT06995677Phase 2
• Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular CarcinomaNot yet recruitingNCT06994572Phase 1
• Immunological Impact of a Post Cell Therapy Treatment With FLT3 InhibitorsNot yet recruitingNCT06992934Not applicable
• Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06992739Phase 2
• Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal CancerRecruitingNCT06992648Phase 3
• Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed GlioblastomaRecruitingNCT06991101Phase 2
• DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET DysregulationsRecruitingNCT06988475Phase 2/3
• A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT06986785Phase 2
• A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström MacroglobulinemiaRecruitingNCT06986174Phase 2
• A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCCNot yet recruitingNCT06984718Phase 2
• A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' DiseaseRecruitingNCT06984627Phase 2
• A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal CancerRecruitingNCT06979908Phase 2
• A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)RecruitingNCT06979596Phase 2
• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque PsoriasisRecruitingNCT06979453Phase 3
• A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLLNot yet recruitingNCT06979076Phase 1/2
• FGF19 Overexpression Combination Unified Study in HCC-19RecruitingNCT06978933Phase 2
• A Study of Brepocitinib in Adults With Cutaneous SarcoidosisRecruitingNCT06978725Phase 2/3
• LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of ThisRecruitingNCT06978088Phase 2
• The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell DiseaseRecruitingNCT06975865Phase 3
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)RecruitingNCT06975618Phase 1/2
• ZR-MTX for PIOL Phase II TrialRecruitingNCT06973811Phase 2
• A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host DiseaseRecruitingNCT06973668Phase 2
• Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian CancerNot yet recruitingNCT06973421Phase 2
• Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT06972641Phase 2/3
• Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI FailureNot yet recruitingNCT06970782Phase 3
• A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain MetastasesRecruitingNCT06970639Phase 3
• Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid CancerRecruitingNCT06970353Phase 2
• Safety and Efficacy of Anlotinib in the Treatment of Recurrent CraniopharyngiomaRecruitingNCT06970145Phase 1/2
• Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C MutationNot yet recruitingNCT06970132Phase 1/2
• A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLCRecruitingNCT06969612Phase 1
• Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).RecruitingNCT06967610Phase 2
• A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCLRecruitingNCT06966154Phase 1/2
• Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell LeukemiaRecruitingNCT06965114Phase 1/2
• Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)RecruitingNCT06962332Phase 1
• Imatinib and Trametinib for KRAS-mutated Solid TumorRecruitingNCT06962254Phase 1
• PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform NeurofibromasRecruitingNCT06961565Phase 1
• Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19RecruitingNCT06960928Phase 3
• Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient StudyRecruitingNCT06959771Phase 1/2
• XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid CancerRecruitingNCT06959641Phase 2
• Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before SurgeryRecruitingNCT06959511Phase 2
• The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical StudyRecruitingNCT06958627Phase 2/3
• Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and LeiomyosarcomaRecruitingNCT06957431Phase 1
• Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver MutationsNot yet recruitingNCT06955325Phase 3
• Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBCRecruitingNCT06955156Phase 2

← Protein Kinase Inhibitors overview